{"id":"doxorubicine-cyclophosphamide-sequential","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Myelosuppression"},{"rate":"5-20%","effect":"Cardiotoxicity"},{"rate":"50-80%","effect":"Nausea and vomiting"},{"rate":"50-80%","effect":"Hair loss"}]},"_chembl":{"chemblId":"CHEMBL1200796","moleculeType":"Small molecule","molecularWeight":"279.10"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Doxorubicin works by inhibiting the enzyme topoisomerase II, which is necessary for DNA replication and transcription. This leads to DNA damage and ultimately cell death. Cyclophosphamide, on the other hand, forms cross-links between DNA strands, which prevents DNA replication and transcription, leading to cell death.","oneSentence":"Doxorubicin is a topoisomerase II inhibitor that intercalates DNA, while cyclophosphamide is an alkylating agent that cross-links DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:53.993Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT01928589","phase":"NA","title":"Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Zellars","startDate":"2014-01-16","conditions":"Breast Cancer, Adenocarcinoma of the Breast","enrollment":81},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT04776525","phase":"PHASE2","title":"Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-04-27","conditions":"Soft Tissue Sarcoma","enrollment":49},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT01897441","phase":"NA","title":"Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-06","conditions":"Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer","enrollment":31},{"nctId":"NCT06401005","phase":"PHASE2","title":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2024-11-28","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT02633137","phase":"PHASE2","title":"Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-12-14","conditions":"Mantle Cell Lymphoma, Untreated","enrollment":49},{"nctId":"NCT03488225","phase":"PHASE2","title":"Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-28","conditions":"Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":4},{"nctId":"NCT06389006","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04-29","conditions":"Breast Cancer","enrollment":79},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT06227117","phase":"PHASE2","title":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-07-27","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT05474690","phase":"PHASE3","title":"A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer","status":"WITHDRAWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-11","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT05848765","phase":"PHASE2","title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2023-09-04","conditions":"Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":284},{"nctId":"NCT01193842","phase":"PHASE1, PHASE2","title":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-06","conditions":"AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma","enrollment":107},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT00656669","phase":"NA","title":"Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Indiana University","startDate":"2008-04","conditions":"Breast Cancer","enrollment":23},{"nctId":"NCT00129922","phase":"PHASE3","title":"Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"1999-11","conditions":"Breast Cancer","enrollment":1289},{"nctId":"NCT02042391","phase":"PHASE2","title":"Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy","status":"COMPLETED","sponsor":"Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH","startDate":"2015-02-03","conditions":"Posttransplant Lymphoproliferative Disorder","enrollment":60},{"nctId":"NCT01516593","phase":"PHASE2","title":"Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"HIV, Burkitt's Lymphoma","enrollment":19},{"nctId":"NCT05400993","phase":"PHASE2","title":"Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT01510184","phase":"PHASE3","title":"Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-04-19","conditions":"Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma","enrollment":79},{"nctId":"NCT01593020","phase":"PHASE2","title":"Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-08-03","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT00558519","phase":"PHASE2","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2008-03-12","conditions":"Leukemia","enrollment":318},{"nctId":"NCT00365417","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT00470301","phase":"PHASE1, PHASE2","title":"Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-04","conditions":"Breast Cancer, Male Breast Cancer, Stage II Breast Cancer","enrollment":60},{"nctId":"NCT01697293","phase":"PHASE1, PHASE2","title":"PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer","status":"TERMINATED","sponsor":"Prescient Therapeutics, Ltd.","startDate":"2012-01","conditions":"Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":34},{"nctId":"NCT00003086","phase":"PHASE1, PHASE2","title":"Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer","status":"TERMINATED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"1997-03","conditions":"Breast Cancer","enrollment":12},{"nctId":"NCT00003088","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1997-09","conditions":"Breast Cancer","enrollment":2005},{"nctId":"NCT01839097","phase":"PHASE1","title":"Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2013-05","conditions":"Peripheral T-cell Lymphoma","enrollment":23},{"nctId":"NCT02115204","phase":"PHASE3","title":"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2000-06","conditions":"Breast Cancer","enrollment":2011},{"nctId":"NCT01049425","phase":"PHASE3","title":"Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2009-02-05","conditions":"Primary Breast Cancer, Her2 Non-overexpressing","enrollment":3198},{"nctId":"NCT03949634","phase":"PHASE3","title":"Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2017-09-01","conditions":"Early Breast Cancer","enrollment":272},{"nctId":"NCT00002565","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1994-05-25","conditions":"Lymphoma","enrollment":61},{"nctId":"NCT00392834","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Lymphoma","enrollment":34},{"nctId":"NCT00404066","phase":"PHASE2","title":"Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer","status":"COMPLETED","sponsor":"George Albert Fisher","startDate":"2006-10","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":21},{"nctId":"NCT02694224","phase":"PHASE2","title":"Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2016-04","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT00590785","phase":"PHASE3","title":"Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-08-13","conditions":"High Risk, Breast Cancer, Positive Nodes","enrollment":60},{"nctId":"NCT00355199","phase":"PHASE3","title":"Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.","status":"COMPLETED","sponsor":"Gruppo Italiano Terapie Innovative nei Linfomi","startDate":"2005-05","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":246},{"nctId":"NCT00148317","phase":"PHASE2","title":"Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2005-06","conditions":"Multiple Myeloma","enrollment":38},{"nctId":"NCT01309789","phase":"PHASE1","title":"A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2011-02","conditions":"Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell, Lymphoma, T-cell","enrollment":39},{"nctId":"NCT00590447","phase":"PHASE2","title":"Risk Stratified Sequential Treatment for CD20-positive PTLD","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2006-12","conditions":"PTLD, Posttransplant Lymphoproliferative Disorder","enrollment":152},{"nctId":"NCT03017404","phase":"NA","title":"A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2015-05","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT01660542","phase":"PHASE4","title":"An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-04","conditions":"Locally Advanced Breast Cancer","enrollment":96},{"nctId":"NCT00635050","phase":"PHASE2","title":"Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2008-03","conditions":"Invasive Breast Cancer","enrollment":32},{"nctId":"NCT00203502","phase":"PHASE2","title":"Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2005-09","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT00455533","phase":"PHASE2","title":"Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-10","conditions":"Breast Cancer","enrollment":384},{"nctId":"NCT00544232","phase":"PHASE3","title":"Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-08","conditions":"Breast Cancer","enrollment":720},{"nctId":"NCT01985841","phase":"PHASE2","title":"Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2011-10","conditions":"Breast Cancer","enrollment":34},{"nctId":"NCT00756470","phase":"PHASE2","title":"Phase II Neoadjuvant in Inflammatory Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-10","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT00425516","phase":"PHASE2","title":"Breast Cancer Treated by Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2007-01","conditions":"Individualized Chemotherapy","enrollment":264},{"nctId":"NCT01985724","phase":"PHASE3","title":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2007-10","conditions":"Breast Cancer","enrollment":650},{"nctId":"NCT00005960","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy","status":"UNKNOWN","sponsor":"Amgen","startDate":"1999-10","conditions":"Pain, Prostate Cancer","enrollment":""},{"nctId":"NCT00003012","phase":"PHASE3","title":"Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Scottish Cancer Therapy Network","startDate":"1996-10","conditions":"Breast Cancer","enrollment":1000},{"nctId":"NCT00011921","phase":"PHASE3","title":"Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"EBMT Solid Tumors Working Party","startDate":"1997-09","conditions":"Lung Cancer","enrollment":430},{"nctId":"NCT00070278","phase":"PHASE3","title":"Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2005-01","conditions":"Breast Cancer","enrollment":800},{"nctId":"NCT00054587","phase":"PHASE3","title":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2001-06","conditions":"Breast Cancer","enrollment":3010},{"nctId":"NCT00003105","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-09","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter","enrollment":30},{"nctId":"NCT00052351","phase":"PHASE2","title":"Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00004906","phase":"PHASE2","title":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"1999-10","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00005908","phase":"PHASE2","title":"Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Breast Cancer, Breast Neoplasm","enrollment":30},{"nctId":"NCT00003953","phase":"PHASE2","title":"Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"1999-02","conditions":"Breast Cancer","enrollment":39},{"nctId":"NCT00002772","phase":"PHASE3","title":"S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"1996-07","conditions":"Breast Cancer","enrollment":602},{"nctId":"NCT00002657","phase":"PHASE2","title":"SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1995-05","conditions":"Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":20},{"nctId":"NCT00000801","phase":"PHASE2","title":"Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Lymphoma, Non-Hodgkin, HIV Infections","enrollment":33},{"nctId":"NCT01159236","phase":"NA","title":"Molecular Triaging of Newly Diagnosed Breast Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00003215","phase":"PHASE3","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"1997-04","conditions":"Lymphoma","enrollment":400},{"nctId":"NCT00149214","phase":"PHASE2","title":"Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-09","conditions":"Breast Cancer","enrollment":257},{"nctId":"NCT00270894","phase":"PHASE2","title":"Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients","status":"COMPLETED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2005-11","conditions":"Breast Neoplasm","enrollment":30},{"nctId":"NCT00721747","phase":"PHASE2","title":"Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer","status":"UNKNOWN","sponsor":"Grupo Oncológico Gallego","startDate":"2008-01","conditions":"Breast Cancer","enrollment":83},{"nctId":"NCT00538395","phase":"NA","title":"Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2007-09","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT00174655","phase":"PHASE3","title":"BIG 02/98 Docetaxel - Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"1998-06","conditions":"Breast Neoplasms","enrollment":2887},{"nctId":"NCT01459887","phase":"PHASE3","title":"Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Shanghai CP Guojian Pharmaceutical Co., Ltd.","startDate":"2006-09","conditions":"Diffuse Large B Cell Lymphoma","enrollment":278},{"nctId":"NCT01458548","phase":"PHASE2","title":"Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2002-12","conditions":"Post-transplantation Lymphoproliferative Disorder","enrollment":70},{"nctId":"NCT00140075","phase":"PHASE3","title":"Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2000-11","conditions":"Adenocarcinoma","enrollment":606},{"nctId":"NCT00231582","phase":"PHASE2","title":"High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2004-09","conditions":"Testicular Neoplasms","enrollment":50},{"nctId":"NCT00314977","phase":"PHASE3","title":"Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2006-02","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT00002679","phase":"PHASE2","title":"Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"1994-02","conditions":"Breast Cancer","enrollment":89},{"nctId":"NCT00033683","phase":"PHASE2","title":"Combination Chemotherapy in Treating Women With Resected Breast Cancer","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2001-02","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00793377","phase":"PHASE3","title":"Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"","conditions":"Primary Breast Cancer","enrollment":913},{"nctId":"NCT00001498","phase":"PHASE2","title":"A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-02","conditions":"Breast Cancer, Breast Neoplasms","enrollment":55},{"nctId":"NCT00431080","phase":"PHASE3","title":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2004-08","conditions":"Breast Cancer","enrollment":478},{"nctId":"NCT00525642","phase":"PHASE2, PHASE3","title":"Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2003-06","conditions":"Breast Neoplasms, Adjuvant, Chemotherapy","enrollment":603}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"doxorubicine + cyclophosphamide sequential","genericName":"doxorubicine + cyclophosphamide sequential","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxorubicin is a topoisomerase II inhibitor that intercalates DNA, while cyclophosphamide is an alkylating agent that cross-links DNA. Used for Breast cancer, Lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}